News

Idorsia starts pivotal Phase 3 trial for Fabry disease drug lucerastat and signs Asia-Pacific deal with Nxera

What's the news? Swiss biotech Idorsia announced on 28 October 2026 that it has started FAB-KLEAR, the pivotal Phase 3 trial of its experimental oral drug lucerastat in adults with Fabry disease, and signed a co-development and commercialisation agreement with Nxera Pharma.

What is Fabry disease? Fabry disease is a rare inherited condition in which the body cannot break down certain fatty substances; they build up in cells and damage organs, particularly the kidneys, heart and nervous system. Current treatments replace the missing enzyme or help it work better, but many patients still face progressive kidney damage. Lucerastat is taken as a pill and works by reducing production of the fatty substances in the first place, so it could work regardless of a patient's specific gene mutation or previous treatment.

Why it matters: FAB-KLEAR is part of an FDA-aligned registration programme designed to show lucerastat reduces fat accumulation in the kidney, a key driver of Fabry-related kidney disease. The trial will enrol 16 adult male patients and, together with a second study called FAB-SWITCH (which compares lucerastat against standard enzyme-replacement therapy), should support a regulatory filing as early as 2029. If successful, lucerastat would be the first oral therapy covering the full spectrum of Fabry patients. The earlier Phase 3 MODIFY study missed its primary pain-reduction endpoint but showed robust biomarker reductions and a signal of slower kidney-function decline.

The deal: Nxera exercised a pre-existing option, paying Idorsia US$6.42M and contributing to the global Phase 3 programme in exchange for exclusive development and commercialisation rights in Japan and selected Asia-Pacific markets (excluding China). Idorsia remains eligible for royalties on net sales in those territories.

Read more: GlobeNewswire, 28 October 2026

More top stories